AI IntelligenceFeb 8, 2026Secondary Market
Article
BIIB
Biogen hit a 52-week high after sales of its Alzheimer's drug Leqembi showed a significant jump. The increase reflects growing adoption and prescriptions for the therapy. The positive development strengthens the company's position in the neurology market.
Data Cube AI EditorialSource: Yahoo Finance
01
Source Brief
Biogen hit a 52-week high after sales of its Alzheimer's drug Leqembi showed a significant jump. The increase reflects growing adoption and prescriptions for the therapy. The positive development strengthens the company's position in the neurology market.
02